Stock Expert AI
Equity research screen

AMGN vs. GILD: Detailed Stock Comparison

This page provides a detailed comparison between Amgen Inc. (AMGN) and Gilead Sciences (GILD). The analysis includes business model considerations relevant to investors interested in the biotechnology sector. This comparison helps to evaluate each company's strengths, weaknesses, and overall investment appeal based on their current market positions.

Quick Answer This page offers an analytical comparison between Amgen (AMGN) and Gilead Sciences (GILD), two significant players in the biotechnology industry. The screen examines their business models and market capitalizations to help investors understand their distinct focuses within pharmaceuticals. Amgen specializes in a wide array of human therapeutics, while Gilead excels in antiviral medications.
Screens40Average score77.00Updated2026-04-10Prices as ofOct 26, 2026 session

Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures.

MoonshotScore V2 rates eligible US-listed companies from 0 to 100 against their sector peers on five pillars: Business Quality (weight 26), Financial Safety (weight 20), Valuation (weight 18), Growth Durability (weight 16) and Momentum (weight 12). It reads no news-sentiment or analyst data, and it is not a probability of future returns.

20,000+ US companies analyzed

Amgen (AMGN) vs. Gilead Sciences (GILD): Key Considerations

Amgen and Gilead represent two established companies in the biotechnology space. Amgen focuses on human therapeutics, while Gilead has a strong presence in antiviral medications. Understanding the nuances of each business is key to informed investment decisions in the pharmaceutical industry.

AMGN vs GILD: The Numbers

Side by side on the figures we publish for both companies. Not a ranking and not a recommendation — the same metrics, read off the same source, on the same day.

AMGN and GILD on five published metrics — MoonshotScore and P/E from our latest stored data; prices, day change and market cap as of the Oct 26, 2026 trading session (FMP quote). Source: Financial Modeling Prep, Yahoo Finance.
Metric AMGNAmgen Inc.GILDGilead Sciences
MoonshotScore 8767
Price $444.63$158.69
Change (1D) +1.22%+1.70%
Market cap $240.4B$196.8B
P/E ratio ——

A dash means we hold no published figure for that company — not a zero. Full analysis: AMGN · GILD.

Shortlist Context

This analysis is designed to provide a high-level overview for investors, and is not a substitute for detailed due diligence. Individual investment decisions should reflect a thorough understanding of personal risk tolerance and financial circumstances.
“MoonshotScore rates a US-listed stock 0 to 100 using five sector-relative pillars. Higher means stronger numbers across business quality, safety, valuation, growth and momentum. Eligible common stocks and ADRs only; funds, ETFs, warrants, units, SPACs, preferreds, and notes carry none. It is built for education and deeper due diligence, not financial advice.”
— Stock Expert AI published methodology (how MoonshotScore works)

Questions worth resolving before acting on the screen

What are the MoonshotScores of AMGN and GILD?

AMGN (Amgen Inc.) has a MoonshotScore of 87 out of 100 and GILD (Gilead Sciences) has 67 (scores dated 2026-10-26). AMGN scores 20 points higher. The MoonshotScore is a model rating, not a recommendation.

What is the latest recorded share price of AMGN and GILD?

AMGN last recorded $444.63 and GILD $158.69 (quotes dated 2026-10-26). These are the last provider quotes we hold, not streaming prices.

Which is larger by market capitalization, AMGN or GILD?

AMGN has a market capitalization of $240.4B and GILD $196.8B (quotes dated 2026-10-26). AMGN is about 1.2 times the size of GILD by market value.

Explore More Research

Stock Expert AI provides data and analysis tools for educational purposes. This is not financial advice. Past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures.